Track topics on Twitter Track topics that are important to you
Asahi Kasei Corp.'s Asahi Kasei Pharma Corp. division will develop and commercialize Array BioPharma Inc.'s tropomyosin receptor kinase A (TrkA) inhibitors for pain, inflammation, and other indication...
Swiss drugmaker Basilea Pharmaceutica has entered into a partnering agreement with Asahi Kasei Pharma…
Array BioPharm and Japan’s Asahi Kasei Pharma Corp have entered a strategic collaboration to develop…
Array BioPharma will partner with Asahi Kasei Pharma on the development and marketing of its tropomyosin receptor kinase A in -More-
* Says that it has entered into a global strategi collaboration agreement with Japanese Asahi Kasei Pharma for the discovery, development and commercialisation of assets in pain management
Asahi Kasei Pharma has become the latest company to join forces with PeptiDream in a research deal.
Finnish pharmaceutical and diagnostics company Orion has entered a global strategic collaboration agreement with Japan-based Asahi Kasei Pharma to discover, develop and commercialise assets in pain ma...
Array BioPharma and Asahi Kasei Pharma announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for p...
The authors conducted a study to assess the effects of yoga on blood pressure (BP). Patients were randomized to yoga (Blood Pressure Education Program [BPEP]), or a combined program (COMBO). Ambulator...
Inability to cross the occlusion with a guidewire is the most common cause of failure of coronary chronic total occlusion (CTO) interventions. We describe two cases of successful application of the no...
In this study, we investigate how measures of insulin secretion and other clinical information affect long-term glycemic control in patients with type 2 diabetes mellitus. Between October 2012 and Jun...